Search Result

Results for "

DM-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (3) ADC Linker (2) Aldose Reductase (1) Antibody-Drug Conjugates (ADCs) (3) Dipeptidyl Peptidase (3) Drug-Linker Conjugates for ADC (11) EGFR (2) Estrogen Receptor/ERR (2) Free Fatty Acid Receptor (1) GCGR (3) Glucosidase (2) GPR119 (1) Microtubule/Tubulin (4) PARP (1) Phosphatase (1) PPAR (1) SGLT (2) Somatostatin Receptor (3) Target Protein Ligand-Linker Conjugates (2) Wnt (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (1) Endocrinology (4) Inflammation/Immunology (1) Metabolic Disease (21)
Click Chemistry:	DBCO (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19792

Mertansine Maximum Cited Publications 18 Publications Verification DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) ^[1] .

HY-101070

SMCC-DM1 5+ Cited Publications DM1-SMCC	Drug-Linker Conjugates for ADC	Cancer
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) ^[1].

HY-100128

DM1-SMe	Microtubule/Tubulin ADC Cytotoxin	Cancer
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC₅₀s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines ^[1].

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-100504

S-methyl DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a K_d of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects ^[1] .

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer ^[1] .

HY-101982A

(Rac)-Lys-SMCC-DM1 (Rac)-Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1 ^[1].

HY-132250

MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues ^[1] .

HY-136286

MC-DM1	Drug-Linker Conjugates for ADC	Cancer
MC-DM1 is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody agent conjugate (ADC) ^[1].

HY-126491

SPP-DM1	Drug-Linker Conjugates for ADC	Cancer
SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP ^[1].

HY-147094

vc-PABC-DM1

ADC Linker Cancer

vc-PABC-DM1 used to synthesize an ADC molecule based on utilize disulfide linker. vc-PABC-DM1 can be used to explore serum stability ^[1].

vc-PABC-DM1	ADC Linker	Cancer
vc-PABC-DM1 used to synthesize an ADC molecule based on utilize disulfide linker. vc-PABC-DM1 can be used to explore serum stability ^[1].

HY-126693

SC-VC-PAB-DM1	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB ^[1].

HY-126682

Mal-VC-PAB-DM1 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB ^[1].

HY-136260

DBCO-PEG4-Ahx-DM1	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-147050

Ahx-DM1	Target Protein Ligand-Linker Conjugates	Others
Ahx-DM1 (compound 2A) is a conjugate of protein/peptide which can be combined with a therapeutic, diagnostic or labelling agent ^[1].

HY-147050A

*Ahx-DM1* TFA**	Target Protein Ligand-Linker Conjugates	Others
Ahx-DM1 (TFA) (compound 2A) is a conjugate of protein/peptide which can be combined with a therapeutic, diagnostic or labelling agent ^[1].

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts ^[1] .

HY-P9921

Trastuzumab emtansine 1 Publications Verification Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[1] .

HY-P9921A

Trastuzumab emtansine (solution) 1 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[1] .

HY-132251

MCC

ADC Linker Cancer

MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1 ^[1].

MCC	ADC Linker	Cancer
MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1 ^[1].

HY-128960

DBA-DM4	Drug-Linker Conjugates for ADC	Cancer
DBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM1 and a linker SPDP to make antibody agent conjugate (ADC) ^[1].

HY-107502

Cryptophycin analog 1	Others	Cancer
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 ^[1].

HY-14928

Lobeglitazone

Others Metabolic Disease

Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

Lobeglitazone	Others	Metabolic Disease
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-14928A

Lobeglitazone sulfate	Others	Metabolic Disease
Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-19947

PF-06291874 Glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-153865

Lotiglipron PF-07081532	GCGR	Metabolic Disease
Lotiglipron (PF-07081532) is an orally active *GLP-1R* agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-114191

SSTR5 antagonist 2	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-114191A

SSTR5 antagonist 2 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-155344

α-Glucosidase-IN-38	Glucosidase	Metabolic Disease
α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC₅₀ of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes mellitus (DM) .

HY-15408

Trelagliptin SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-117103

AMG131 INT131	PPAR	Metabolic Disease
AMG131 (INT131), a potent and highly selective PPARγ partial agonist, binds to PPARγ and displaces Rosiglitazone with a K_i of ~10 nM. AMG131 can be used for research of type-2 diabetes mellitus (T2DM) .

HY-15408A

Trelagliptin succinate SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-12066

GSK1292263 3 Publications Verification	GPR119	Metabolic Disease Inflammation/Immunology
GSK-1292263 is an orally available GPR119 agonist with pEC₅₀s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-147257

Cofrogliptin HSK7653	Dipeptidyl Peptidase	Metabolic Disease
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .

HY-149332

α-Glucosidase-IN-26	Glucosidase	Metabolic Disease
α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC₅₀=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .

HY-128781

Glucagon receptor antagonists-5	GCGR	Metabolic Disease
Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (K_i=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-19835

LY2922470	Free Fatty Acid Receptor	Metabolic Disease
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC₅₀s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .

HY-132205

DS45500853	Estrogen Receptor/ERR	Metabolic Disease
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-143201

DS20362725	Estrogen Receptor/ERR	Metabolic Disease
DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-149255

PTP1B/AKR1B1-IN-2	Phosphatase Aldose Reductase	Metabolic Disease
PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual *PTP1B/AKR1B1* inhibitor (IC₅₀s: 3.2 and 2.1 μM, K_is: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM) .

3-Hydroxypalmitoylcarnitine 3-Hydroxyhexadecanoylcarnitine	Biochemical Assay Reagents
3-Hydroxypalmitoylcarnitine (3-Hydroxyhexadecanoylcarnitine) is an acylcarnitine. Elevated levels of 3-Hydroxypalmitoylcarnitine are associated with cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701665

	DMPK Protein, Human (Sf9) DMPK; Myotonin-protein kinase; MT-PK; DM-kinase; DMK; DM1 protein kinase; DMPK; Myotonic dystrophy protein kinase	Human	Sf9 insect cells
	DMPK is a non-receptor serine/threonine protein kinase that is critical for skeletal muscle integrity, affecting myocyte differentiation, nuclear membrane integrity, and muscle-specific gene expression. It may inhibit myosin phosphatase (PPP1R12A), regulate myosin phosphorylation and affect cardiac contractility and conduction. DMPK Protein, Human (Sf9) is the recombinant human-derived DMPK protein, expressed by Sf9 insect cells , with tag free. The total length of DMPK Protein, Human (Sf9) is 629 a.a., .

HY-P701666

	DMPK Protein, Human (Sf9, His) DMPK; Myotonin-protein kinase; MT-PK; DM-kinase; DMK; DM1 protein kinase; DMPK; Myotonic dystrophy protein kinase	Human	Sf9 insect cells
	DMPK is a non-receptor serine/threonine protein kinase that is critical for skeletal muscle integrity, affecting myocyte differentiation, nuclear membrane integrity, and muscle-specific gene expression. It may inhibit myosin phosphatase (PPP1R12A), regulate myosin phosphorylation and affect cardiac contractility and conduction. DMPK Protein, Human (Sf9, His) is the recombinant human-derived DMPK protein, expressed by Sf9 insect cells , with N-6*His labeled tag. The total length of DMPK Protein, Human (Sf9, His) is 629 a.a., .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote